Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Plocabulin - PharmaMar

Next Previous
Search
Drug Profile

Plocabulin - PharmaMar

Alternative Names: PM-184; PM-60184; PM060184

Latest Information Update: 05 Dec 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator PharmaMar
  • Class Amines; Antineoplastics; Carbamates; Pyrans; Small molecules
  • Mechanism of Action Tubulin polymerisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Breast cancer; Colorectal cancer
  • No development reported Solid tumours

Most Recent Events

  • 05 Dec 2023 Chemical structure information added
  • 20 Oct 2023 Efficacy, adverse events, PK and drug-drug interaction data from phase I trial in Solid tumours presented at the 48th European Society for Medical Oncology Congress (ESMO-2023)
  • 28 Sep 2023 No recent reports of development identified for phase-I development in Solid-tumours(Combination therapy, Late-stage disease) in USA (IV, Infusion)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top